Abdominal Obesity
Conditions
Keywords
Abdominal Obesity, training, fat, insulin, glucose, diet
Brief summary
In this project, the investigators will test the hypothesis that predominant (two to three times a week 60 min) strength training is more effective in reducing visceral fat mass than endurance training in obese patients.
Detailed description
Strength training (ST) was shown to be more effective than endurance training (ET) in improving glycemic control in the treatment of type 2 diabetes. However, it is unknown, whether different training strategies have different effects on the preferential visceral adipose tissue reduction and changes in resting energy expenditure in a population with abdominal obesity. We will therefore compare ST and ET (two to three times a week, 60 minutes per training session) in addition to a restricted energy intake of 1500kcal per day for women and 1800kcal per day for men in a prospective study of 200 individuals with abdominal obesity defined by a waist circumference \> 102 cm for males and \> 88 cm for females and a BMI \> 35 kg/m² with regard to: 1. Abdominal visceral adipose tissue area dynamic (MRI studies) 2. Abdominal subcutaneous adipose tissue area dynamic (MRI studies) 3. Total body fat mass changes (bioelectrical impedance analysis) 4. Changes in resting energy expenditure (indirect calorimetry) 5. Changes in parameters of glucose metabolism, insulin sensitivity and lipid profile 6. Changes in circulating adipokines and markers of inflammation In addition, we will search for novel serum parameters, which predict the individual training response by a serum metabolomics/ proteomics approach.
Interventions
PROCEDUREexercise training
comparison of strength versus endurance training (two or three times a week, 60 minutes per training session) over 24 months
Sponsors
University of Leipzig
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* BMI \>= 35 kg/m2 * waist circumference \>102cm (men), \>88cm (women) * age 18 - 60 years * written informed consent
Exclusion criteria
* type 1 or type 2 diabetes * fasting plasma glucose \>= 6.0 mmol/l * 2h-OGTT (oral glucose tolerance test) glucose \>= 11.1 mmol/l * any chronic inflammatory or malignant disease * medical treatment which influences glucose metabolism * drug or alcohol abuse * psychiatric disorders * untreated thyroid dysfunction * cardiac pacemaker or other contraindication for MRI * attendant therapy with oral antidiabetic medication, GLP-1 mimetics or analoga, Insulin, anti-obesity medication (orlistat, sibutramine), Falithrom, antipsychotic drugs, any chemotherapeutics * pregnant or nursing women * expected low compliance * current participation in another investigational trial * last exercise training \<= 6 months ago
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MRI | Baseline and after 12 months after randomisation | Change from Baseline in abdominal visceral fat area as determined by MRI scans at the level of L4-L5 after 12 months of training intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| BIA | Baseline, 6, 12, 18 and 24 months after randomisation | Changes from Baseline in total body fat mass |
| compliance to the intervention | over 24 months of intervention | compliance to the intervention of training (strength or endurance) as measured by the number of realized training units. Non-compliance = cumulative time bigger than six weeks per year |
| well being as measured by SF-36 | Baseline and every 6 months during intervention | Changes from Baseline in individual well being as measured by SF-36 |
| MRI | Baseline, 12 and 24 months after randomisation | Changes from Baseline in abdominal visceral and subcutaneous fat area |
| fasting plasma glucose | Baseline and every 12 months | Changes from Baseline in fasting plasma glucose, insulin sensitivity and insulin secretion determined in oral glucose tolerance tests |
| inflammatory parameters | Baseline and every 3 months during intervention | Changes from Baseline in inflammatory parameters |
| adipokine serum concentrations | Baseline and every 3 months during intervention | Changes from Baseline in adipokine serum concentrations |
| indirect calorimetry | Baseline, 6, 12, 18 and 24 months after randomisation | Changes from Baseline in resting energy expenditure |
Countries
Germany
Contacts
Primary ContactMatthias Blüher, prof., MD
Backup ContactNicole Bauernfeind
Outcome results
None listed